Pulmonary  ||| S:0 E:10 ||| JJ
arterial  ||| S:10 E:19 ||| JJ
hypertension  ||| S:19 E:32 ||| NN
in  ||| S:32 E:35 ||| IN
adults  ||| S:35 E:42 ||| NNS
with  ||| S:42 E:47 ||| IN
congenital  ||| S:47 E:58 ||| FW
heart  ||| S:58 E:64 ||| FW
disease  ||| S:64 E:72 ||| FW
Pulmonary  ||| S:72 E:82 ||| FW
arterial  ||| S:82 E:91 ||| FW
hypertension  ||| S:91 E:104 ||| FW
( ||| S:104 E:105 ||| -LRB-
PAH ||| S:105 E:108 ||| NNP
)  ||| S:108 E:110 ||| -RRB-
is  ||| S:110 E:113 ||| VBZ
a  ||| S:113 E:115 ||| DT
common  ||| S:115 E:122 ||| JJ
problem  ||| S:122 E:130 ||| NN
in  ||| S:130 E:133 ||| IN
adult  ||| S:133 E:139 ||| NN
patients  ||| S:139 E:148 ||| NNS
with  ||| S:148 E:153 ||| IN
congenital  ||| S:153 E:164 ||| JJ
heart  ||| S:164 E:170 ||| NN
disease ||| S:170 E:177 ||| NN
.  ||| S:177 E:179 ||| .
We  ||| S:179 E:182 ||| PRP
review  ||| S:182 E:189 ||| VBP
available  ||| S:189 E:199 ||| JJ
data  ||| S:199 E:204 ||| NNS
on  ||| S:204 E:207 ||| IN
aetiology ||| S:207 E:216 ||| NN
,  ||| S:216 E:218 ||| ,
clinical  ||| S:218 E:227 ||| JJ
presentation ||| S:227 E:239 ||| NN
,  ||| S:239 E:241 ||| ,
prognosis  ||| S:241 E:251 ||| NN
and  ||| S:251 E:255 ||| CC
management  ||| S:255 E:266 ||| NN
of  ||| S:266 E:269 ||| IN
PAH  ||| S:269 E:273 ||| NNP
in  ||| S:273 E:276 ||| IN
this  ||| S:276 E:281 ||| DT
setting ||| S:281 E:288 ||| NN
.  ||| S:288 E:290 ||| .
In  ||| S:290 E:293 ||| IN
addition ||| S:293 E:301 ||| NN
,  ||| S:301 E:303 ||| ,
we  ||| S:303 E:306 ||| PRP
discuss  ||| S:306 E:314 ||| VB
general  ||| S:314 E:322 ||| JJ
management  ||| S:322 E:333 ||| NN
strategies  ||| S:333 E:344 ||| NNS
and  ||| S:344 E:348 ||| CC
emerging  ||| S:348 E:357 ||| VBG
disease-targeting  ||| S:357 E:375 ||| JJ
therapies ||| S:375 E:384 ||| NNS
.  ||| S:384 E:386 ||| .
